Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases responses rates. An international randomised phase II study in metastatic breast cancer

Annals of Oncology

Volumn 8, Issue 2, 1997, Pages 155-162

  Brufman, G ^a   Colajori, E ^b   Ghilezan, N ^c   Lassus, M ^b,d   Martoni, A ^e   Perevodchikova, N ^f   Tosello, C ^g   Viaro, D ^b   Zielinski, C ^h  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b PFIZER INC   (United States)

^c THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^d CIBA GEIGY LTD   (Switzerland)

^e Ospedale St Ursola Malpighi   (Italy)

^f INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^g Praca Amadeu Amaral   (Brazil)

^h UNIVERSITY OF VIENNA   (Austria)

Author keywords

dose intensification; epirubicin; metastatic breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0031040985     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008295427877     Document Type: Article

References (42)

1. Wingo P, Tong T, Bolden S. Cancer statistics, 1995. CA 1995; 45: 8-30.
2. Henderson IC, Harris JR. Principles in the management of metastatic disease. In Harris JR, Hellman S, Henderson IC, Kinne DW (eds): Breast Diseases, 2nd edition. Philadelphia: JB Lippincolt Company 1991.
3. Greenberg PAC, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-205.
4. Aisner J, Weinberg V, Perloff M et al. Chemotherapy versus chemoimmunotherapy (CAF vs. CAFVP vs. CMF each ±MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 1987; 5: 1523-33.
5. Tormey D, Weniberg V, Leone L et al. A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. Am J Clin Oncol 1984; 7: 231-9.
6. Bull J, Tormey D, Carbone P et al. A randomised comparative trial of adriamycin vs. methotrexate on combination drug therapy. Cancer 1978; 41: 1649-57.
7. Cunnings F, Gelman R, Horton J. Comparison of CAF vs. CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol 1985; 3: 932-40.
8. Smalley R, Lefante J, Bertolucci A et al. A comparison of cyclophosphamide, adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate and 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat 1983; 3: 209-20.
9. Hryniuk W, Figueredo A, Goodyear M. Applications of dose intensity to the problems in chemotherapy of breast cancer and colorectal cancer. Semin Oncol 1987; 4 (Suppl 4): 3-11.
10. Italian Multicentric Study with Epirubicin. Phase III randomised study of fluorouracil, epirubicin and cyclophosphamide vs. fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: An Italian multricenter trial. J Clin Oncol 1988; 6: 976-82.
11. Brambilla C, Rossi A, Bonfante V et al. Phase II study of doxorubicin vs. epirubicin in advanced breast cancer. Cancer Treat Rep 1986; 70: 261-6.
12. The French Study Group. A prospective randomised phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncol 1988; 6(4): 679-88.
13. Carmo Pereira J, Henriques E, Costa F et al. Epirubicin as first-line chemotherapy in disseminated breast carcinoma. A phase II study. Preliminary results. Proc Am Soc Oncol 1989; 116 (Abstr).
14. Blackstein M, Wilson K, Meharchand J et al. Phase I study of epirubicin in metastatic breast cancer. Proc Am Soc Oncol 1988; 87 (Abstr).
15. Sledge G, Roth B, Munshi N et al. High dose epirubicin as initial therapy for advanced breast cancer. Proc Am Soc Clin Oncol 1992; 11: 85 (Abstr).
16. Bastholt L, Dalmark M, Gjedde S et al. Epirubicin at four different dose levels in metastatic breast cancer. A randomised trial. JCO 1996; 14: 1146-55.
17. Camaggi CM, Strocchi E, Carisi P et al. Epirubicin metabolism and pharmacokinetics after conventional and high-dose intravenous administration: A cross-over study. Cancer Chemother Pharmacol 1993; 32: 301-9.
18. Miller A, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
19. Schipper H, Clinch J, McMurray A et al. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472-83.
20. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Controlled Clin Trials 1981; 2: 93-113.
21. Focan C, Andrein JM, Closon Mth et al. Dose response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomised trial. J Clin Oncol 1993; 11: 1253-63.
22. Crown J. High-dose chemotherapy of solid tumors. Ann Oncol 1995; 6 (Suppl 1): S11-S15.
23. Langleben A, Alhgren P, Radoux S et al. Ultra-high-dose anthracycline combination therapy, with peripheral blood stem cell (PBSC), G-CSF and ADR-529 support. Proc Am Soc Oncol 1995; 948 (Abstr).
24. Ejlertsen B, Pfeiffer P, Pedersen D et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastasic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 1993; 29A (4): 527-31.
25. Praga C, Trave F, Petroccione A. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. In Nimmo WS (ed): Clinical Measurement in Drug Evaluation. London: Wolfe Publishing Ltd 1991; 131-42.
26. Calero F, Jimeno J, Rodriguez Escudero F et al. Epirubicin: Clinical toxicity during phase II program in endometrial and cervical cancer. Eur J Gynaecol Oncol 1992; 13: 83-9.
27. Nielsen D, Jensen J, Dombernowsky P et al. Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 1990; 8: 1806-10.
28. Mourdisen H. The role of anthracyclines in adjuvant chemotherapy of breast cancer: A critical appraisal. Fifth International Conference on Adjuvant Therapy of Primary Breast Cancer. St. Gallen. Anti-Cancer Drugs, 1995; 6 (Suppl 2): S20 (Abstr).
29. Levine M, Bramwell V, Browman D et al. A clinical trial of intensive CEF vs. CMF in premenopausal women with node positive breast cancer. Proc Am Soc Oncol 1995; 112 (Abstr).
30. Bonneterre J, Roché H, Bremond A et al. A randomized trial of adjuvant chemotherapy with FEC 50 vs. FEC 100 for node-positive operable breast cancer. Early report. Proc Am Soc Clin Oncol 1996; 15: 82 (Abstr).
31. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiothepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992; 10: 102-10.
32. Peters W, Eder J, Henner W et al. High-dose combination alkylant agents with autologous bone marrow support: A phase I trial. J Clin Oncol 1986; 4: 646-54.
33. Dunphy F, Spitzer G, Buzdar A et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marron support. J Clin Oncol 1990; 8: 1207-16.
34. Kennedy M, Beveridge R, Rowley S et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1920-6.
35. Peters W, Shpall E, Jones R et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-76.
36. Verweij J, Clavel M and Chevalier B. Paclitaxel and docetaxel: Not simply two of a kind. Ann Oncol 1994; 5: 495-506.
37. Gruia G, Misset J, Giacchetti S et al. A phase I-II study of taxotere in combination with adriamycin as first-line chemotherapy in patients with metastatic breast cancer. Proc Am Soc Oncol 1995; 258 (Abstr).
38. Munzone E, Gianni L, Capri G et al. Cardiac function in breast cancer patients given paclitaxel by 3 hours infusion and previous concomitant doxorubicin. Proc Am Soc Oncol 1995; 211 (Abstr).
39. Spielmann M, Catimel G, Dieras V et al. A phase I study of taxol (paclitaxel) and farmorubicin (epirubicin) in metastatic breast cancer: Preliminary results. Proc Am Soc Oncol 1995; 256 (Abstr).
40. Habeshaw T, Paul J, Jones R et al. Epirubicin at two dose levels with prednisone as treatment for advanced breast cancer: The results of a randomised trial. J Clin Oncol 1991; 9: 295-304.
41. Marschner N, Kreienberg R, Souchon R et al. Evaluation of the epirubicin dose intensity in combination with a fixed dose of cyclophosphamide in metastatic breast cancer. Nineteenth Congress of the ESMO (Lisbon, Portugal). Ann Oncol 1994; 5 (Suppl 8): 126 (Abstr).
42. The French Epirubicin Study Group. A prospective randomised trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991; 9 (2): 305-12.